| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.albertdavidindia.com | |
| Market Cap | 307.56 Cr. | |
| Enterprise Value(EV) | 292.76 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 61.78 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 8.72 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 29.26 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 489.69 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 1.10 | Calculated using Price: 538.90 |
| Dividend Yield | 1.67 | Period Ending 2021-03 |
| No. of Shares Subscribed | 0.57 Cr. | 5,707,162 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Albert David was incorporated in the year 1938. The company is a part of Kothari group. Albert David, which has decades of illustrious presence in the health care industry, manufactures pharmaceutical formulations and bulk drugs, infusion solutions and oral solids, disposable syringes and needles and herbal formulations. The company exports these products to Vietnam, Russia, Belarus, Egypt, Bangladesh, Kenya, Tanzania, Uganda, Sudan, Ethiopia, Nigeria, Zaire, Haiti, Brazil, Canada, USA, UK, Netherlands and Germany as the company is a WHO-approved supplier. It also has DMF for the bulk drugs, Tolbutamide and Chlorpropamide with the US Food and Drugs Administration (USFDA). The manufacturing facility for these products has been inspected and validated by the US drug regulator. The manufacturing plants of the company are located at Ghaziabad near New Delhi, Kolkata and Mandideep near Bhopal. The company`s amino acid range under the brand name of Alamin contains pure crystalline amino acid of high international standards manufactured under a unique technology, which conforms to WHO and FAO recommendations. In the herbal segment, the company sells its products under brand names like Adliv, which is a hepato protective and Siotone capsule, which is the only adaptogen indicated for stress. ADL has tie-ups with Ajinomoto Co and Roussel Morishita Co of Japan for manufacturing and marketing a wide range of crystalline amino acid infusion solutions, oral solids and liquids in India. Products offered by the Company: The company is operating in major therapeutic segments that include:
Future Plans: |
||
Company Profile
Albert David was incorporated in the year 1938. The company is a part of Kothari group.
Albert David, which has decades of illustrious presence in the health care industry, manufactures pharmaceutical formulations and bulk drugs, infusion solutions and oral solids, disposable syringes and needles and herbal formulations. The company exports these products to Vietnam, Russia, Belarus, Egypt, Bangladesh, Kenya, Tanzania, Uganda, Sudan, Ethiopia, Nigeria, Zaire, Haiti, Brazil, Canada, USA, UK, Netherlands and Germany as the company is a WHO-approved supplier.
It also has DMF for the bulk drugs, Tolbutamide and Chlorpropamide with the US Food and Drugs Administration (USFDA). The manufacturing facility for these products has been inspected and validated by the US drug regulator.
The manufacturing plants of the company are located at Ghaziabad near New Delhi, Kolkata and Mandideep near Bhopal.
The company`s amino acid range under the brand name of Alamin contains pure crystalline amino acid of high international standards manufactured under a unique technology, which conforms to WHO and FAO recommendations. In the herbal segment, the company sells its products under brand names like Adliv, which is a hepato protective and Siotone capsule, which is the only adaptogen indicated for stress.
ADL has tie-ups with Ajinomoto Co and Roussel Morishita Co of Japan for manufacturing and marketing a wide range of crystalline amino acid infusion solutions, oral solids and liquids in India.
Products offered by the Company:
The company is operating in major therapeutic segments that include:
Future Plans:The company will explore the possibilities for export of its IV fluids, small volume parenterals and disposable syringes in addition to its existing range.
| 1 Day |
|
+1.55% |
| 1 Week |
|
+3.33% |
| 1 Month |
|
-9.87% |
| 3 Month |
|
-6.49% |
| 6 Month |
|
-9.78% |
| 1 Year |
|
+21.76% |
| 2 Year |
|
+9.78% |
| 5 Year |
|
+69.41% |
| 10 Year |
|
+558.00% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 10.93 | 14.67 | 14.96 | 41.80 | 9.98 | 5.33 | 13.44 | 8.85 | 9.48 | |
| Return on Capital Employed (%) | 14.45 | 17.79 | 18.22 | 46.48 | 14.29 | 7.94 | 20.60 | 13.74 | 11.99 | |
| Return on Assets (%) | 4.15 | 5.30 | 5.52 | 19.35 | 5.18 | 2.77 | 7.23 | 4.95 | 5.51 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 81 | 90 | 93 | 137 | 183 | 186 | 210 | 223 | 244 | 279 | |
| Non Curr. Liab. | 42 | 59 | 14 | 8 | 9 | 15 | 20 | 27 | 26 | 14 | |
| Curr. Liab. | 86 | 115 | 125 | 120 | 159 | 160 | 145 | 149 | 135 | 109 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 210 | 265 | 231 | 265 | 351 | 361 | 376 | 398 | 405 | 403 | |
| Non Curr. Assets | 95 | 123 | 74 | 69 | 116 | 118 | 113 | 130 | 127 | 149 | |
| Curr. Assets | 115 | 141 | 158 | 196 | 234 | 243 | 263 | 268 | 278 | 254 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 210 | 265 | 231 | 265 | 351 | 361 | 376 | 398 | 405 | 403 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 265 | 291 | 322 | 323 | 295 | 290 | 317 | 321 | 247 | 314 | |
| Other Income | 2 | 1 | 2 | 2 | 16 | 10 | 21 | 7 | 17 | 16 | |
| Total Income | 267 | 291 | 324 | 325 | 311 | 300 | 339 | 328 | 265 | 329 | |
| Total Expenditure | -239 | -258 | -285 | -291 | -277 | -275 | -288 | -290 | -228 | -273 | |
| PBIDT | 28 | 33 | 39 | 33 | 34 | 25 | 51 | 38 | 36 | 57 | |
| Interest | -4 | -4 | -3 | -2 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Depreciation | -11 | -11 | -15 | -9 | -8 | -8 | -7 | -8 | -8 | -9 | |
| Taxation | -5 | -6 | -7 | -15 | -10 | -6 | -16 | -10 | -5 | -12 | |
| Exceptional Items | 41 | ||||||||||
| PAT | 9 | 13 | 14 | 48 | 16 | 10 | 27 | 19 | 22 | 35 | |
| Adjusted EPS | 15 | 22 | 24 | 84 | 28 | 17 | 47 | 34 | 39 | 62 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 11 | 20 | 21 | 28 | 68 | 20 | 30 | 32 | 30 | 37 | |
| Cash Fr. Inv. | -12 | -9 | -24 | -9 | -38 | -37 | -11 | -19 | -20 | -37 | |
| Cash Fr. Finan. | -11 | -8 | -2 | -18 | -18 | 7 | -5 | -17 | -10 | -2 | |
| Net Change | -12 | 3 | -5 | 1 | 12 | -10 | 14 | -4 | 0 | -2 | |
| Cash & Cash Eqvt | 12 | 15 | 9 | 10 | 22 | -4 | 11 | 6 | 6 | 5 |
|
Fri, 13 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we enclose herewith a copy of the Extract of the Audited Financial Results of the Company for the Quarter and Financial Year ended March 31 2022 as published in terms of Regulation 47 of the Listing Regulations in English newspaper i.e. Financial Express (all India) and vernacular newspaper (Bengali) i.e. Aajkal on May 12 2022. |
|
Wed, 11 May 2022
Considered/Approved The Audited Financial Results For The Quarter And Financial Year Ended March 31 2022 Along With The Auditors Report (With Unmodified Opinion) Considered/Approved the Audited Financial Results for the quarter and financial year ended March 31 2022 along with the Auditors Report (with unmodified opinion) |
|
Wed, 11 May 2022
Board recommends Dividend Albert David Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 11 2022 inter alia have Recommended a dividend of Rs. 9/- per equity shares of Rs. 10/- each for the financial year ended March 31 2022 subject to approval of the shareholders at the forthcoming Annual General Meeting of the Company. |
| Fri, 20 May 2022 |
High Delivery Percentage
|
Closing Above Previous High
|
High Decrease 1 Month
|
| Thu, 19 May 2022 |
|
High Decrease 1 Month
|
William %R Crossed -80 From Above
|
Equities
M.F.
Sectors